University of Alabama at Birmingham: Neurofibromatosis 1 trials

The registry lists 10 Neurofibromatosis 1 studies with University of Alabama at Birmingham as lead sponsor. 3 are open to participants now and 7 have results posted.

Phase 2 9No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade GliomaNot yet recruitingNCT07521657Phase 2
• Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1RecruitingNCT06188741Phase 2
• Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for SarcomasRecruitingNCT05253131Phase 2
• Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform NeurofibromasCompletedNCT03231306Phase 2Results posted
• A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)TerminatedNCT02718131Not applicableResults posted
• Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and AdultsCompletedNCT02101736Phase 2Results posted
• MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1CompletedNCT02096471Phase 2Results posted
• Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular SchwannomasCompletedNCT01767792Phase 2Results posted
• A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1CompletedNCT00853580Phase 2Results posted
• A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform NeurofibromasCompletedNCT00634270Phase 2Results posted